Docoh
Loading...

ALT Altimmune

News

From Benzinga Pro
Altimmune Q3 EPS $(0.81) Down From $(0.54) YoY, Sales $200.00K Down From $2.94M YoY
9 Nov 21
Earnings, News
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.81) per share. This is a 50 percent decrease over losses of $(0.54) per share from the same period last year. The company reported $200.00 thousand in sales this
Altimmune Granted U.S. Patent #11,141,477 'Rapid and prolonged immunologic-therapeutic'
12 Oct 21
News
View patent here
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep 21
Biotech, Earnings, M&A, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29)
52 Biggest Movers From Yesterday
30 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday.
12 Health Care Stocks Moving In Wednesday's Intraday Session
29 Sep 21
Intraday Update, Markets, Movers
33 Stocks Moving In Wednesday's Mid-Day Session
29 Sep 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Paltalk, Inc. (NASDAQ: PALT) shares climbed 37% to $7.18.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
29 Sep 21
Pre-Market Outlook, Markets, Movers
H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off
28 Sep 21
Analyst Color, Biotech, Long Ideas, News, Health Care, Price Target, Reiteration, Small Cap, Analyst Ratings, Movers, Trading Ideas, General
H.C. Wainwright said that Altimmune Inc (NASDAQ: ALT) reported "positive" Phase 1 trial pemvidutide data, formerly known as ALT-801, in obese patients.
See Why Altimmune Stock Plunged After Obesity Trial Data
28 Sep 21
Biotech, News, Health Care, Small Cap, Movers, Trading Ideas, General
Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist.
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
28 Sep 21
Biotech, News, Penny Stocks, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27)
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
28 Sep 21
Pre-Market Outlook, Markets, Movers
12 Health Care Stocks Moving In Monday's After-Market Session
27 Sep 21
Movers
Gainers

Press releases

From Benzinga Pro
Altimmune to Present at Upcoming Investor and Scientific Conferences
22 Nov 21
News, Health Care, Press Releases
GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be presenting virtually
Altimmune to Present at Upcoming Investor Conferences
10 Nov 21
News, Health Care, Press Releases
GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be presenting virtually
Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
9 Nov 21
Earnings, Press Releases
Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to undetectable levels after 6 weeks of treatment Approximately $200
Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021
3 Nov 21
News, Health Care, Press Releases
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday,
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
15 Oct 21
Press Releases
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact
Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
6 Oct 21
News, Press Releases
GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting virtually at the
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
1 Oct 21
Press Releases
New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ:ALT). Such investors are advised to
Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021
29 Sep 21
News, Press Releases
GAITHERSBURG, Md., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its 12-week Phase 1
Thinking about buying stock in Farmmi, Naked Brand, Southwestern Energy, Altimmune, or Rewalk Robotics?
28 Sep 21
Opinion, Press Releases
NEW YORK, Sept. 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FAMI, NAKD, SWN, ALT, and RWLK.
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
28 Sep 21
Analyst Ratings, Press Releases
Mean weight loss of 10.3% achieved in subjects receiving 1.8 mg dosePemvidutide was well-tolerated without the need for dose titration No discontinuations due to treatment-emergent adverse eventsNASH IND has cleared FDA
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
27 Sep 21
News, Press Releases
GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 clinical trial of
Thinking about buying stock in Vizio, Li-Cycle Holdings, Matinas BioPharma, Frontline, or Altimmune?
27 Sep 21
Opinion, Press Releases
NEW YORK, Sept. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VZIO, LICY, MTNB, FRO, and ALT.
Thinking about buying stock in Nabriva Therapeutics, WiMi Hologram Cloud, Xos Inc, Altimmune, or Penn National Gaming?
8 Sep 21
Opinion, Press Releases
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBRV, WIMI, XOS, ALT, and PENN.
Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
7 Sep 21
News, Press Releases
GAITHERSBURG, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at